Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBM AGILE Global Adaptive Trial Master Protocol
2024-511452-40-00Phase 3Authorised
- Sponsor
- Global Coalition for Adaptive Research
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised trial of Pegargiminase, troriluzole and azd1390 in glioblastoma (GBM) and Gliosarcoma (GS) (4 arms), sponsored by Global Coalition for Adaptive Research. Primary endpoint: Overall Survival. Planned start Jul 2024; status: authorised.
02
Drugs
Pegargiminasetroriluzoleazd1390
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on 2024-511452-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511452-40-00.